Key Moments
260 ‒ Men’s Sexual Health: why it matters, what can go wrong, and how to fix it
Peter Attia MDKey Moments
Comprehensive guide to men's sexual health: ED, PE, testosterone, prostate cancer, and treatment options.
Key Insights
Male sexual dysfunction, including ED, PE, and Peyronie's disease, is highly prevalent and often suffered in silence due to embarrassment and lack of physician inquiry.
Erectile Dysfunction (ED) is directly linked to cardiovascular disease, serving as an early indicator of endothelial dysfunction.
Lifestyle modifications (diet, exercise, sleep, stress reduction) are crucial for improving ED and overall sexual health.
Phosphodiesterase-5 (PDE5) inhibitors, particularly daily tadalafil, not only treat ED but may also offer preventative benefits by improving cavernous smooth muscle health.
Post-finasteride syndrome, characterized by irreversible sexual and neurological side effects, is a concerning and potentially underreported issue.
Testosterone replacement therapy (TRT) has been largely exonerated from causing prostate cancer and may even be protective; however, it has implications for fertility.
Premature Ejaculation (PE) treatment includes topical anesthetics, SSRIs (often off-label), and behavioral therapies, with a strong emphasis on addressing underlying psychological factors.
Advanced ED treatments include penile injections and implants, offering effective solutions when oral medications fail, alongside emerging therapies like shockwave therapy with cautious optimism.
THE SILENT EPIDEMIC OF MALE SEXUAL DYSFUNCTION
Male sexual dysfunction, encompassing conditions like erectile dysfunction (ED), premature ejaculation (PE), and Peyronie's disease (PD), is remarkably common across all adult age groups. Surveys indicate that a significant percentage of men experience these issues, with ED affecting over 50% of men over 40, and 7-9% of men having PD. Despite its widespread prevalence and significant impact on quality of life, including links to depression and anxiety, most men suffer in silence. This reluctance to seek help stems from embarrassment and a general lack of inquiry from healthcare providers, who often prioritize other health concerns during routine check-ups.
UNDERSTANDING THE ANATOMY AND INTERCONNECTEDNESS OF MALE REPRODUCTIVE HEALTH
The male sexual system is a complex interplay of the urinary, reproductive, and sexual systems. The penis, often seen as a single organ, comprises three systems: the urethra for urinary function, and two corpora cavernosa for erections. The testes produce sperm and testosterone, while the prostate and seminal vesicles contribute to seminal fluid. All these systems are interconnected, meaning dysfunction in one can affect the others. For instance, medications for benign prostatic hyperplasia (BPH) can cause retrograde ejaculation, affecting both fertility and sexual function. This holistic view is crucial for effective diagnosis and treatment.
ERECTILE DYSFUNCTION: PREVALENCE, DEFINITION, AND ROOT CAUSES
Erectile dysfunction is defined using validated questionnaires like the IIEF, determining mild, moderate, or severe ED. Its prevalence increases with age, roughly following the 40/50/60/70 rule for men in their respective decades. However, age itself is not the primary cause; rather, it’s the acquisition of comorbid conditions. ED is categorized by the mnemonic VENT: Vascular, Endocrine, Neurologic, and Trauma (including Peyronie’s disease), with medications also playing a role. Psychogenic ED, more common in younger men, is distinguished by the ability to achieve erections during masturbation or upon awakening.
PHARMACOLOGICAL SOLUTIONS FOR ERECTILE DYSFUNCTION
The primary pharmacological approach to ED involves phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) and tadalafil (Cialis). These medications block phosphodiesterase, preventing the breakdown of cyclic GMP, thus prolonging the vasodilation necessary for an erection. Discovered serendipitously (Viagra was initially developed for blood pressure), PDE5 inhibitors have revolutionized ED treatment. While they don't cure ED, they effectively manage symptoms. Daily low-dose tadalafil is favored for its potential to improve endothelial function and promote smooth muscle hypertrophy, offering both symptomatic relief and a possible preventative measure against disease progression.
THE INTRINSIC LINK BETWEEN ED AND CARDIOVASCULAR HEALTH
Erectile dysfunction is a significant prognostic indicator for cardiovascular disease (CVD). Studies show that men developing ED have a substantially increased risk of heart attack or stroke within seven years. This correlation is primarily due to endothelial dysfunction, a common underlying pathology for both conditions. Risk factors for ED—such as obesity, diabetes, smoking, and hypertension—are nearly identical to those for CVD. Improving these lifestyle factors can not only enhance erectile function but also reverse endothelial dysfunction, highlighting the systemic importance of addressing ED beyond sexual health.
DIAGNOSING AND ADVANCED TREATMENTS FOR ERECTILE DYSFUNCTION
Beyond questionnaires, diagnostic tools include penile ultrasound with intracavernosal injection of vasodilators like trimix. This allows for measurement of peak systolic velocity (assessing arterial inflow) and end-diastolic velocity (indicating venous leak), pinpointing hemodynamic issues. For patients unresponsive to oral medications, second-line therapies include penile injections, which deliver vasodilators directly into the corpora cavernosa. Penile implants, a tertiary option, involve surgically placing inflatable cylinders, providing a reliable and on-demand erection. These advanced options offer significant improvement in quality of life for men with severe or refractory ED.
PEYRONIE'S DISEASE: CAUSES, SYMPTOMS, AND MANAGEMENT
Peyronie's disease (PD), characterized by penile curvature due to plaque formation in the tunica albuginea, affects 7-9% of men. It is often caused by trauma during intercourse, which leads to abnormal healing. Symptoms include penile pain during erection, especially in the active phase (first 12 months), and a curvature that can impede intercourse. Treatment options include Xiaflex (collagenase) injections to break down plaque, surgical plication or grafting for severe curvature, and mechanical traction devices (off-label but increasingly used) to straighten and potentially lengthen the penis. Early intervention, particularly with traction, holds promise for better outcomes.
THE PROMISE AND PITFALLS OF REGENERATIVE AND SHOCKWAVE THERAPIES
Emerging ED treatments like stem cell therapy, platelet-rich plasma (PRP), and low-intensity extracorporeal shockwave therapy (LI-ESWT) offer new avenues. Shockwave therapy, though still investigational, is gaining traction due to its non-invasive nature and ability to induce neoangiogenesis and recruit stem cells. However, its efficacy varies, and many commercial 'gainswave' clinics use less effective radial shockwave devices, exploiting vulnerable patients. Stem cell and PRP therapies, while showing some promise in research, currently lack consistent, large-scale, placebo-controlled trials, and regulatory approval, making them costly and often unproven outside of specific research protocols.
PREMATURE EJACULATION: DEFINITION, TYPES, AND THERAPEUTIC STRATEGIES
Premature ejaculation (PE) affects up to 30% of men but only a fraction seek treatment. It's defined by decreased ejaculatory time (often less than 2 minutes for lifelong PE or 50% reduction for acquired PE), loss of control, and personal bother. PE can be lifelong (due to hypersensitivity or neurobiological factors) or acquired (often linked to hormonal changes or psychological stress). Treatments include topical lidocaine sprays, selective serotonin reuptake inhibitors (SSRIs) (daily or on-demand, though with potential side effects like reduced libido), and behavioral techniques like the 'start-stop' or 'squeeze' methods taught by sex therapists. When ED and PE coexist, treating ED first often resolves PE.
DELAYED EJACULATION AND ANORGASMIA: DIAGNOSIS AND TREATMENT CHALLENGES
Delayed ejaculation (DE) and anorgasmia involve prolonged time to ejaculation (e.g., greater than 15-20 minutes) or inability to orgasm, respectively. Diagnosis relies on patient-reported bother and, ideally, stopwatch-measured intravaginal ejaculatory latency time (IELT). Unlike other sexual dysfunctions, there are no FDA-approved treatments for DE or anorgasmia, making all therapies off-label. Common causes include SSRI use, though dose adjustments can sometimes mitigate this. Testosterone replacement therapy is an off-label treatment option, as low testosterone is linked to impaired orgasm. Five-alpha reductase inhibitors are generally avoided due to their potential to induce anorgasmia.
TESTOSTERONE PHYSIOLOGY AND REPLACEMENT THERAPY OPTIONS
Testosterone production is regulated by the hypothalamic-pituitary-gonadal (HPG) axis, involving GnRH, LH, and FSH. LH stimulates Leydig cells to produce testosterone, while FSH stimulates Sertoli cells for sperm production. Most testosterone is bound to albumin and sex hormone-binding globulin (SHBG), with only 2% being free and biologically active. While total testosterone levels may not significantly decline with healthy aging, SHBG often increases, leading to lower free testosterone. Treatment decisions for low testosterone prioritize symptoms over numbers. Replacement options include oral, injectable (subcutaneous preferred), intranasal, and pellet formulations, each with distinct advantages and disadvantages regarding cost, convenience, and efficacy.
THE UNEXPECTED ROLE OF TESTOSTERONE IN PROSTATE CANCER
The long-held belief that testosterone causes prostate cancer, originating from a 1941 study, has been largely debunked. Current guidelines indicate no association between testosterone replacement therapy (TRT) and increased prostate cancer risk. Emerging research even suggests testosterone may be protective against prostate cancer. Notably, 'bipolar androgen therapy' (BAT) involves giving high doses of testosterone to men with metastatic castrate-resistant prostate cancer, showing comparable or even improved survival compared to standard androgen deprivation therapies, with significantly better quality of life and lower cost. The 'prostate saturation model' posits that prostate growth plateaus at certain testosterone levels, negating the linear relationship previously assumed.
CHALLENGES WITH FIVE-ALPHA REDUCTASE INHIBITORS (5-ARI'S)
Five-alpha reductase inhibitors (5-ARIs) like finasteride and dutasteride, primarily used for BPH and hair loss, are highly controversial due to the risk of Post-Finasteride Syndrome (PFS). PFS involves persistent, irreversible sexual, neurological, and psychological side effects even after discontinuing the drug. The mechanism extends beyond simply blocking DHT conversion; 5-ARIs also disrupt the synthesis of essential neurosteroids like allopregnanolone, which influences depression, anxiety, and cognition. While official medical bodies acknowledge prolonged side effects, consensus on PFS's existence as a distinct syndrome varies. Many clinicians, however, are increasingly cautious given the potential for severe, life-altering consequences and elevated suicide risk among affected individuals.
NAVIGATING HORMONE THERAPY: RISKS, BENEFITS, AND FERTILITY CONSIDERATIONS
Testosterone replacement therapy (TRT) requires careful consideration, especially for younger men, due to its suppressive effect on endogenous testosterone production and spermatogenesis. While TRT can improve energy, libido, and muscle mass, it can lead to infertility. HCG (human chorionic gonadotropin) is often used alongside TRT to preserve testicular size and function, or as a standalone therapy to stimulate endogenous testosterone production, particularly for fertility. Oral and intranasal testosterone formulations are emerging as alternatives to injections and gels, with some evidence suggesting less suppression of spermatogenesis. Open communication between patient and physician is vital for informed decision-making regarding TRT, balancing symptomatic relief with potential risks.
Mentioned in This Episode
●Products
●Tools
●Companies
●Organizations
●Studies Cited
●Concepts
●People Referenced
Ejaculatory Time by SSRI (Waldinger 2004)
Data extracted from this episode
| SSRI | Ejaculatory Latency Time Increase (x) |
|---|---|
| Paroxetine | 25x |
| Sertraline (Zoloft) | 10x (~) |
Testosterone Delivery Methods Comparison
Data extracted from this episode
| Method | Cost (Monthly) | Dosing Frequency | User Experience | Pros | Cons |
|---|---|---|---|---|---|
| Testosterone Cypionate (SubQ, compounded) | $25 | Twice weekly | Self-injection, minimal pain | Physiologic levels, cheapest, stable levels | Needle phobia, user error |
| XyosTed (Testosterone Enanthate, pre-loaded) | $150 | Once weekly | Pre-loaded auto-injector | Convenient, no user error | More expensive than compounded |
| Testosterone Pellets | Variable | Every 3-4 months | Minor surgical implantation | Long-lasting, no daily action | Peak/trough fluctuations, initial discomfort, short inactivity period, cost |
| Oral Testosterone Undecanoate (Jatenzo, Tlando, Kyzatrex) | Variable (insurance dependent) | Twice daily | Pill with meal | Convenient, no injections/implants, no hepatotoxicity | No absorption fasting, strict timing with meals, titration challenges |
| Néstor (Nasal Testosterone) | Variable (insurance dependent) | Three times daily | Nasal spray | Fast onset, no significant spermatogenesis suppression | Frequent administration |
| Testosterone Gels/Creams | Variable (insurance dependent) | Once daily | Topical application | Non-invasive | Poor/variable absorption, transference risk, inconvenient, lower levels |
Common Questions
Roughly 40% of men report some form of sexual dysfunction. Only about half of those would like treatment, but 51% don't tell their doctor and 44% don't tell their partner due to embarrassment. Clinicians also often don't ask about it due to time constraints.
Topics
Mentioned in this video
A foundational study from 1941 that led to the long-held belief that testosterone causes prostate cancer, based on observations from a single patient.
Where Dr. Mo A. A. earned his MBA. His wife also attended medical school there.
A urologist and friend of Peter Attia, mentioned as a prominent urologist.
A drug used to treat female sexual dysfunction, initially developed as an antidepressant, which increases sexual desire in women.
The first FDA-approved treatment for Peyronie's disease in 2015, injected into the plaque to break down collagen and improve curvature.
A medication commonly used as a sleep agent that can, in rare cases, induce priapism (prolonged erection).
A pre-loaded injectable testosterone enanthate product using a 27-gauge needle for ease of use, costing more than compounded cypionate.
An organization of urologists and other healthcare professionals specializing in sexual medicine, dedicated to advancing research and patient care in this field.
A therapy for ED involving injecting concentrated platelets from a patient's own blood into the penis, but currently lacks strong scientific evidence. Often marketed as the 'P-Shot'.
A controversial but recognized condition where men experience irreversible sexual and neurological symptoms (ED, libido loss, depression, suicidal ideation) even after stopping finasteride. The mechanism is thought to involve silencing of key neurosteroid genes.
An androgen receptor blocker used as standard of care for castrate-resistant metastatic prostate cancer, often compared with bipolar androgen therapy.
One of the two main suppliers of penile prosthesis devices, known for its hydrophilic device that can absorb antibiotics.
A mimetic for LH, used to stimulate Leydig cells to produce testosterone, preserving testicular volume and sperm production when used with exogenous testosterone. Was previously widely compounded but now restricted and costly.
A penile traction device from the Mayo Clinic that bends the penis in the opposite direction of curvature, used for 30 minutes twice a day for 3 months, showing 30-40% improvement in curvature and potential for length/girth increase.
A non-invasive treatment for ED that induces neoangiogenesis and recruits stem cells through trauma, with some evidence of benefit for mild to moderate ED using Class Type 3 (electrohydraulic/electromagnetic) machines.
Medications primarily used for BPH, but can also prolong ejaculatory time as a second-line treatment for premature ejaculation, with a risk of retrograde ejaculation.
Where Dr. Mo A. A. completed his general surgery internship, urology residency, and male reproductive medicine and surgery fellowship. He is now on faculty there.
A phosphodiesterase-5 inhibitor often prescribed daily at 5mg for psychogenic ED to break the 'vicious cycle' of anxiety, and also for BPH and pulmonary hypertension. It's suggested as a preventative measure for smooth muscle health.
A commercially available medication that can be injected into the corpus cavernosum to induce an erection.
Antidepressants that can be used off-label to prolong ejaculatory time, though they may have side effects like reduced libido and ED.
A genetic abnormality (XXY chromosome) in men, leading to infertility, gynecomastia, and typically low testosterone, requiring treatment with testosterone to raise levels, especially if fertility is not a concern.
A 5-alpha reductase type 2 inhibitor, initially approved for BPH (Proscar 5mg), and later for hair loss (Propecia 1mg). Strongly criticized due to its potential link to Post-Finasteride Syndrome and increased suicide rates.
A validated questionnaire used to diagnose and assess the severity of erectile dysfunction.
The institution where Dr. Mo A. A. underwent his undergraduate education.
A diagnostic tool used to assess blood flow (peak systolic and end diastolic velocity) and detect plaque in the penis, often after an injection to induce an erection.
A newer phosphodiesterase-5 inhibitor with less cross-reactivity with other phosphodiesterases, potentially leading to fewer side effects like back pain or vision changes.
A compounded medication containing papaverine, phentolamine, and prostaglandin, injected into the penis to induce vasodilation and an erection for diagnostic ultrasounds or as a second-line ED treatment.
A narcotic medication listed as a second-line therapy for premature ejaculation, but carries a high risk of addiction.
An unconventional therapy for metastatic prostate cancer where high doses of testosterone are given to convert castrate-resistant cancer cells to castrate-sensitive ones, showing promising results in studies.
An over-the-counter numbing agent applied to the penis 10 minutes before sex to treat premature ejaculation by decreasing sensitivity of the glans.
An injectable form of testosterone, favored for older patients due to potentially less sodium retention, given subcutaneously.
A company that provides shockwave therapy devices for erectile dysfunction, noting that it's a brand name for a technology with variable device quality.
A phosphodiesterase-5 inhibitor that blocks the enzyme phosphodiesterase, increasing cyclic GMP to maintain erections. It was originally developed as a blood pressure medication.
Mentioned as potentially the single most potent agent for women's sexual health, particularly estrogen, due to its synergistic effects with other medications.
A condition characterized by plaque formation in the penile tunica albuginea, leading to abnormal curvature, pain during erection, and often disfigurement. Believed to be caused by trauma during intercourse.
One of the two main suppliers of penile prosthesis devices, notable for its antibiotic-coated implants (minocycline-rifampin).
A promising, but unapproved and unproven, therapy for ED that involves injecting autologous adipose-derived stem cells into the penis, with effects lasting 6-9 months in early studies.
A Selective Estrogen Receptor Modulator (SERM) used to increase endogenous testosterone by blocking estrogen receptors, but can have side effects like reduced libido and desire in men due to central estrogen receptor blockade.
An injectable form of testosterone, favored for younger patients due to its anabolic properties, given subcutaneously for cost-effectiveness and stable levels.
An isomer of Clomid that was developed to avoid the estrogen receptor blockage centrally and adverse sexual side effects seen with Clomid, but is only available compounded and hard to get.
A surgical implant consisting of two inflatable cylinders, a pump, and a reservoir, allowing men to manually induce and maintain an erection. It has been used for 50 years and is a highly effective treatment option.
An alpha-blocker used to treat BPH, preferred for younger men due to its lower rate of retrograde ejaculation compared to other alpha-blockers.
Two simple questions used to quickly ascertain if a patient has erectile dysfunction: 'Are you able to get an erection sufficient for penetration?' and 'Are you able to maintain that erection until orgasm?'
An intranasal testosterone delivery system, applied three times a day, which does not significantly suppress spermatogenesis and provides quick onset of action.
A prominent cancer research and treatment institution, with a study on testosterone after radical prostatectomy.
The professional organization that sets guidelines for urological conditions, including testosterone therapy and Peyronie's disease.
Where Dr. Mo A. A. attended medical school.
An injectable drug used to treat female sexual dysfunction, similar in effect to Addyi but not as impactful as Viagra for men.
A dietary pattern recommended for improving endothelial dysfunction and erectile dysfunction, as shown in the Esposito 2004 study.
An antidote injected into the penis to reverse priapism, particularly effective if administered within four hours of onset.
Oral testosterone formulations that bypass hepatotoxicity by being absorbed through the lymphatic system, requiring intake with a fatty meal. Multiple brands are now FDA approved.
A 5-alpha reductase type 1 and type 2 inhibitor, used to treat BPH. Also associated with similar, though less prominent, side effects as finasteride.
A study that demonstrated the reversal of ED through diet and exercise (Mediterranean diet) in obese men, showing significant improvement in IIEF scores and endothelial function.
Another phosphodiesterase-5 inhibitor for erectile dysfunction.
A large, 6,000-patient randomized placebo-controlled trial on testosterone in men, set to be published in June for its cardiovascular outcomes, addressing previous concerns.
More from Peter Attia MD
View all 121 summaries
135 min381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more
9 minIs Industrial Processing the Real Problem With Seed Oils? | Layne Norton, Ph.D.
13 minCooking with Lard vs Seed Oils | Layne Norton, Ph.D.
146 min380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Found this useful? Build your knowledge library
Get AI-powered summaries of any YouTube video, podcast, or article in seconds. Save them to your personal pods and access them anytime.
Try Summify free